ASXL1 and cholangiocarcinoma: A recent analysis of patients aged 15 through 45 years with cholangiocarcinoma demonstrated that younger patients were more likely to carry additional sex combos like 1 (ASXL1) and lysine methyltransferase 2c (KMT2C) mutations compared with older patients with cholangiocarcinoma.7